Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)
Registered Office:
3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033
T: +91 40 23635000,
E: investorrelations@viyash.com
Website: www.viyash.com
CIN: L99999TS1985PLC196357

Date: August 12, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip code: 512529

National Stock Exchange of India Limited
Exchange Plaza, Bandra
Kurla Complex, Bandra (E),
Mumbai - 400 051.

Symbol: VIYASH

Dear Sir/Madam,

Subject: Investor Presentation for Q1 FY 2026-27

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.

This is for your information and appropriate dissemination.

Thanking you.

Yours faithfully,
For Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

YOSHITA SUSMIT VORA
Digitally signed by YOSHITA SUSMIT VORA
Date: 2026.08.12 09:48:09 +05'30'

Yoshita Vora
Company Secretary

INVESTOR PRESENTATION

Q1 FY27

VIYASH SCIENTIFIC LIMITED

August 12, 2026

Marching ahead as an Integrated platform

Viyash

Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing our strategic focus on the companion animal segment, providing us with market access and a platform to launch our product portfolio in key European markets. As we move forward, our focus remains on disciplined execution, operational efficiency, and strategic investments in line with our long-term strategy for sustainable growth.

Dr Hari Babu Bodepudi

Viyash Scientific Limited

Q1FY27 Financial Snapshot

Viyash Scientific : Q1 FY27 Performance Highlights

All values in ₹ Mn

Revenues

₹9,464

Million

+19.5%
YoY

EBITDA[1]

₹2,047

Million

+59.2 %
YoY

EBITDA Margin

21.6%

+530 bps
YoY

Net Debt to LTM EBITDA[1]

0.1x

Net Debt- ₹ 861 Mn

0.2x
in Q4 FY26
Net Debt - ₹ 1,661

Notes: 1. EBITDA are adjusted for ESOP costs

Sustained Sales Growth with Consistent EBITDA Expansion

All values in ₹ Mn









*EBITDA adjusted for ESOP

Viyash Consolidated Financials

All values in ₹ Mn

Particulars	Q1 FY27	Q1 FY26	Grw YoY %	Q4 FY26	Grw QoQ %	FY26	FY25	Grw YoY %
Revenue from Operations	9,464	7,916	*19.5%*	9,200	*2.9%*	34,203	30,068	*13.8%*
Material Consumption	(4,343)	(3,805)		(4,128)		(15,627)	(14,702)	
Gross Margin	**5,121**	**4,111**	*24.6%*	**5,071**	*1.0%*	**18,576**	**15,367**	*20.9%*
% Gross margin	*54.1%*	*51.9%*		*55.1%*		*54.3%*	*51.1%*	
Employee Benefit Expenses	(1,381)	(1,258)	9.7%	(1,445)	-4.5%	(5,293)	(4,959)	6.7%
Operating Expenses	(1,696)	(1,573)	7.8%	(1,689)	0.5%	(6,378)	(5,984)	6.6%
Exchange Gain / (Loss)	3	6		63		120	(23)	
EBITDA[1]	**2,047**	**1,286**	*59.2%*	**2,001**	*2.3%*	**7,025**	**4,400**	*59.6%*
% EBITDA	*21.6%*	*16.2%*		*21.7%*		*20.5%*	*14.6%*	
ESOP cost	(246)	(130)		(53)		(362)	(561)	
Exceptional Items	-	(13)		(0)		(442)	(816)	
IndAS 29 Adjustment	(14)	37		(42)		(17)	29	
Other Income	80	62		96		315	329	
Finance Cost	(125)	(204)		(145)		(692)	(864)	
Depreciation	(618)	(556)		(604)		(2,336)	(2,387)	
Earnings Before Tax	**1,124**	**483**	*132.8%*	**1,252**	*-10.2%*	**3,490**	**132**	*2569.4%*
% Earning Before Tax	*11.9%*	*6.1%*		*13.6%*		*10.2%*	*0.4%*	
Taxes	(331)	(115)		(589)		(1,244)	26	
Earnings After Tax	**793**	**369**	*114.9%*	**664**	*19.4%*	**2,246**	**158**	*1334.0%*

- ESOP cost increase on account of incremental ESOP grants pursuant to the scheme of amalgamation
- Finance Cost reduction on account of the reduction in debt.

Notes: 1. EBITDA are adjusted for ESOP costs

Business Updates

Business Segments Performance

All values in ₹ Mn

Revenue Distribution	Q1			Q4		12M		
	FY27	FY26	YoY %	FY26	QoQ %	FY26	FY25	YoY %
Formulations	**5,547**	**4,170**	***33%***	**4,991**	*11%*	**18,657**	**15,828**	*18%*
Europe	1,847	1,640	*13%*	1,733	*7%*	6,682	5,614	*19%*
Emerging Markets	2,008	1,480	*36%*	1,725	*16%*	6,305	5,142	*23%*
India	430	263	*63%*	379	*13%*	1,405	1,155	*22%*
USA	1,262	787	*60%*	1,154	*9%*	4,266	3,916	*9%*
APIs	**3,833**	**3,692**	***4%***	**3,836**	*0%*	**14,906**	**13,747**	***8%***
Other Sales	75	92		184		423	372	
Global Sales	**9,455**	**7,954**	**19%**	**9,011**	**5%**	**33,987**	**29,946**	***13%***
One Offs #		(56)				(56)	(74)	
Adjustment* - Ind AS 29*	8	19		189		273	196	
Reported Sales	**9,464**	**7,916**	***20%***	**9,200**	***3%***	**34,203**	**30,068**	***14%***

**Adjustment on account of hyperinflation in Turkey as per Ind AS 29*

 # Provision for customer claim on shipments in prior years

Bio For Life acquisition in Italy

Acquisition of Bio for Life in Italy aligned with our Companion strategy

01 Provides access to a large companion animal market in Italy

02 Companion animal portfolio (85-90 products) that can be extended to other core markets

03 Launch our global pipeline in Italy; salesforce has 85% vet clinic coverage in Italy

04 Strong talent addition in Italy

Execution of SPA: 21st July 2026
Expected Closing Timeline: September 2026

Additional Business Updates

Facility Inspections

- **4** Regulatory Audits
- **66** Customer audits

Regulatory Approvals

- **3 APIs-** (USDMF-1 ; EDMF-1; CEP-1)
- **2 FDF -** US (2)

Launches

- **6 APIs** (2-MENA, 1-EU, 1 CHINA, 1 LATAM)
- **4 FDF**

Products Filed

- **8 APIs** – USDMF (1),USVMF(1), Russia (2), Taiwan (1), Singapore (1), Malaysia (1), US VMF (1)
- **2 FDF -** US (2)

Validations Completed

- **15 APIs**
- **4 FDF**

R&D Pipeline

- **API:** 85+
- **Human FDF:** 24+
- **Animal FDF:** 81+

Viyash at a Glance

Who we are?

We are an integrated pharmaceutical platform across animal and human health backed by science and IP

Diversified Product Portfolio

API - 90+

Human Health - 30+

Animal Health- 140+

Global Presence

150+ Countries

250+ global customers

Backward Integration

16 Manufacturing facilities

Backward Integration for key APIs

IP & Technology Driven

250+ Scientists

175+ Patents Filed

1,000+ Registrations

Strong Management Team

Industry leaders with 30+ years experience

Viyash Scientific: Key Milestones

Viyash Life Sciences

Foundation & Early Growth
2019–2020

Founded in February 2019 by Dr Haribabu Bodepudi.

Rapid expansion through acquisitions of Vindhya Pharma and Vandana Life Sciences, and establishment of API R&D infrastructure.

Scale & Expansion
2021

Acquisition of Mylan's API and formulation units in Vizag and Mumbai. Strategic investment by the Carlyle Group.

Acquisition of Symed Labs and Appco Pharma LLC, strengthening global capabilities

Integration & Global Reach
2022–2025

Unified manufacturing operations, expanded R&D to over 200 scientists, filed 175+ patents*, and strengthened global partnerships and regulatory capabilities.

Viyash Scientific Limited

2025 onwards

Foundation & Evolution
1985–2013

Originated as Visistha Trades, transitioned into a focused pharmaceutical and animal health company, and rebranded as SeQuent Scientific Limited.

Global Expansion
2014–2019

Established Alivira as a dedicated animal health brand. Expanded operations across Europe, Latin America, and emerging markets with USFDA veterinary API approvals.

Specialization & Growth
2020–2025

Focused on new geographies and specialized animal healthcare segments, building a strong global manufacturing and distribution network.

SeQuent Scientific

16 world class manufacturing facilities



Our R&D landscape

Viyash

R&D centre	Location	Capabilities / dosage forms	Technologies & infrastructure	R&D members
API R&D	India (Hyderabad, Telangana)	• Scalable complex APIs incl. high-potent (OEB 4/5) & cytotoxic; iron-complex, inorganic & complex molecules	• 20+ chemical R&D labs; dedicated process-safety lab; high-end analytical equipment for process dev & validation	225+
Formulation R&D – Human Health (Viyash / Appco)	India	• OSD (Non-Onco) & Onco-Cytotoxic; generics plus complex pharmaceuticals	• Formulation development, analytical method development, tech transfer, QA, regulatory affairs	60+
Formulation R&D – Animal Health (Alivira)	India, Spain, Turkey	• Generic & complex dosage forms — solid, liquid & sterile (oral solutions/suspensions, powders, premixes)	• Formulation development, analytical method development, tech transfer, QA, regulatory filings	55+

Board of Directors

Dr. Kamal Sharma
Chairman and Independent Director

Dr. Haribabu Bodepudi
Managing Director and Group CEO

Mr. Rajaram Narayanan
Executive Director and CEO- Animal Health

Mr. Anuj Poddar
Non-executive Director

Mr. Amit Jain
Non-executive Director

Mr. Abhiroop Jayanthi
Non-executive Director

Mr. Milind Sarwate
Independent Director

Ms. Revati Kasture
Independent Director

Mr. Srinivas Vasireddy
Executive Director

Growth drivers

Long Term Strategy

Animal formulations	Companion Animals	✓ New product development ✓ Market expansion ✓ Manufacturing expansion ✓ M&A
	Farm Animals	✓ Portfolio completion ✓ Geography extension
API & CDMO		✓ Portfolio expansion ✓ Day 1 launch ✓ Complex CDMO
Human formulations		✓ API integrated play ✓ Complex products including oncology

For details, feel free to contact:

Yoshita Vora

Company Secretary

+91 22 4111 4777

investorrelations@viyash.com

Abhishek Singhal

Investor Relations Consultant

abhishek@arunya.co.in

Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India

Websites: www.viyash.com | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: VIYASH

ISIN: INE807F01027

Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India

info@viyash.com | www.viyash.com